...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic (R) nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer
【24h】

Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic (R) nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer

机译:通过透明质酸装饰的混合Pluronic纳米粒子递送胎醌,以减弱三阴性乳腺癌的血管生成和转移

获取原文
获取原文并翻译 | 示例

摘要

Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic subtype of breast cancer showing nonresponsiveness to most available therapeutic options. Therefore, smart therapeutic approaches to selectively transport and target TNBCs are required. Herein, we developed thymoquinone (TQ)-loaded, hyaluronic acid (HA)-conjugated Pluronic (R) P123 and F127 copolymer nanoparticles (HA-TQ-Nps) as a selective drug-carrying vehicle to deliver anticancer phytochemical TQ to TNBC cells. The mean size of nanoparticles was around 19.3 +/- 3.2 nm. and they were stable at room temperature up to 4 months. HA-TQ-Nps were immensely cytotoxic towards TNBC cells but did not show the toxic effect on normal cells. Detailed investigations also demonstrated its pro-apoptotic, anti-metastatic and anti-angiogenic activity. In-depth mechanistic studies highlighted that HA-TQ-Nps retarded cell migration of TNBC cells through up-regulation of microRNA-361 which in turn down-regulated Rac1 and RhoA mediated cell migration and also perturbed the cancer cell migration under the influence of the autocrine effect of VEGF-A. Moreover, HA-TQ-Np-treatment also perturbed tumor-induced vascularization by reducing the secretion of VEGF-A. The anti-metastatic and anti-angiogenic activity of HA-TQNps was found to be evident in both MDA-MB-231 xenograft chick embryos and 4T1-mammary solid tumor model in syngeneic mice. Thus, an innovative targeted nano-therapeutic approach is being established to reduce the tumor burden and inhibit metastasis and angiogenesis simultaneously for better management of TNBC.
机译:三阴性乳腺癌(TNBC)是乳腺癌的高侵袭性和转移性亚型,显示出最可用的治疗选择的非反应性。因此,需要选择性地运输和靶向TNBC的智能治疗方法。在此,我们开发了替喹啉(TQ) - 加载的透明质酸(HA) - 缀合的PluronicP123和F127共聚物纳米颗粒(HA-TQ-NPS)作为选择性药物的载体,以将抗癌植物化学TQ输送到TNBC细胞。纳米颗粒的平均尺寸约为19.3 +/- 3.2nm。它们在室温下保持稳定,长达4个月。 HA-TQ-NPS朝向TNBC细胞的细胞毒性,但没有显示对正常细胞的毒性作用。详细的调查还证明了其促凋亡,抗转移性和抗血管生成活性。深入的机制研究强调了通过微润罗纳-361的上调迁移TNBC细胞的HA-TQ-NPS延迟细胞迁移,这反而调节的RAC1和rhOA介导的细胞迁移,并且在影响的影响下也扰乱了癌细胞迁移VEGF-A的自分泌效果。此外,通过减少VEGF-A的分泌,HA-TQ-NP治疗也扰乱了肿瘤诱导的血管化。发现HA-TQNP的抗转移性和抗血管生成活性在SyngeeicC鼠的MDA-MB-231异种移植鸡胚和4T1-乳腺固体瘤模型中是显而易见的。因此,正在建立一种创新的靶向纳米治疗方法,以减少肿瘤负荷,并同时抑制转移和血管生成,以便更好地管理TNBC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号